매크로 컨텍스트

테마

K-Bio & Drug Development

핵심 동인

  • Global CDMO market growing 10%+ annually
  • Plant 5 brings total capacity to 780kL (global #1)
  • Expanding orders for next-gen biologics including ADCs and bispecific antibodies
  • Order backlog at record $10B+ level

리스크

  • Intensifying CDMO competition (WuXi, Lonza)
  • Reduced orders if global bio investment slows
  • FX volatility risk (profitability declines with KRW appreciation)
  • Uncertainty in recovering large-scale capex

애널리스트 컨센서스

최저 1,200,000 KRW최고 2,300,000 KRW
현재가컨센서스 목표가

2026. 6. 16. 기준

증권사애널리스트목표가투자의견
투자 기간: 12개월

모니터링 트리거

핵심 지표

  • Quarterly order amount trends
  • Utilization rate (including Plant 5)
  • ADC/bispecific antibody order share
  • Gross margin trend

리뷰 트리거

  • Quarterly orders decline 20%+ QoQ
  • Plant 5 utilization rate below 50%
  • CDMO competitor wins large order

무효화 조건

  • Two consecutive years of order decline
  • Prolonged utilization rate below 30%
  • Large contract termination due to quality issues

Related ETFs

ETFs covering the same theme as 207940.KS — alternatives when direct holding is constrained or diversification is preferred

All ETFs

Comments

생성: 2026. 2. 24.수정: 2026. 2. 24.가격 기준: 2026. 6. 16.